Depomed sues FDA to get sales exclusivity for shingles pain drug
(Reuters) - Depomed Inc filed a lawsuit against U.S. health regulators, seeking market exclusivity for its shingles pain drug, which was designated as an orphan drug.
The U.S. Food and Drug Administration, which approved Gralise in January 2011, had granted orphan-drug designation to it, but not the market exclusivity that goes with the status.
An orphan drug status, granted to drugs treating fewer than 200,000 patients, gives the approved product seven years of marketing exclusivity from its approval date.
Gralise accounted for $3.2 million, or 23 percent of Depomed's sales in its latest quarter.
Menlo Park, California-based Depomed shares, which have slipped 7 percent since Gralise was approved, closed at $5.77 on Tuesday on the Nasdaq.
(Reporting by Vidya P L Nathan; Editing by Don Sebastian)
- Google bus blocked in San Francisco gentrification protest
- Obama and Castro shake hands, Zuma humiliated at Mandela memorial |
- Thai PM urges protesters to take part in election |
- SEC votes to adopt Volcker rule to ban proprietary trading
- Reporter allowed to keep sources secret in Colorado theater shooting
Protesters block several main streets in Kiev, responding to calls from opposition leaders to defend their demonstration from possible police intervention. Slideshow